CMA
PTCT icon

Cedar Mountain Advisors’s PTC Therapeutics PTCT Stock Holding History

Cedar Mountain Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245 Buy
+3
New +$217 ﹤0.01% 1111
2026
Q1 		– Sell
-2
Closed -$152 – 1191
2025
Q4 		$152 Buy
+2
New +$145 ﹤0.01% 685

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Cedar Mountain Advisors's PTCT Position: Q2 2026 in Review

Cedar Mountain Advisors opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 3 shares worth $245. The stake represents ﹤0.01% of the portfolio and ranks #1111 among its holdings. This is a return to the name: Cedar Mountain Advisors previously reported a position in PTCT as recently as Q4 2025.

Cedar Mountain Advisors first reported a position in PTCT in Q4 2025 and has held it in 2 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Cedar Mountain Advisors held 3 shares of PTC Therapeutics worth $245 as of Q2 2026.
  • PTC Therapeutics was a new Cedar Mountain Advisors position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #1111 holding.
  • Cedar Mountain Advisors first reported a position in PTC Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.